Anti-Human EGFR (Cetuximab Biosimilar)
Catalog #500014
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500014 | 1 mg | $150.00 | ||
| 500014 | 5 mg | $500.00 | ||
| 500014 | 20 mg | $1,250.00 |
Product Details
Cetuximab biosimilar is a chimeric (mouse/human) IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is developed as a cost-effective alternative to the reference biologic Cetuximab (Erbitux®) while maintaining comparable efficacy, safety, and quality. This biosimilar is designed for preclinical and translational research in oncology, particularly in the study of colorectal cancer, head and neck squamous cell carcinoma (HNSCC), and other EGFR-expressing tumors.
Specifications
| Clone | Cetuximab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.2 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human EGFR / ErbB-1 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |